Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al.
Matejicka
Colleen
C
Morgan
G James
GJ
Schlegelmilch
John G
JG
D000328:Adult; D001175:Arthrography; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D015616:Histiocytosis, Non-Langerhans-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007596:Joints / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D006886:Hydroxychloroquine; D000068800:Etanercept